Atezolizumab Approval Sets Stage for Future Drug Development in TNBC

April 18, 2019 – The impact of the March 2019 FDA approval of atezolizumab plus nab-paclitaxel in patients with locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC) is unmistakable, but according to Mariana Chavez Mac Gregor, MD, MSc, other agents of considerable merit include PARP inhibitors and antibody-drugs conjugates (ADCs). The decision to approve the PD-L1 inhibitor atezolizumab was based on data from the phase … (leggi tutto)